Guinness Asset Management LTD Acquires 4,268 Shares of AbbVie Inc. $ABBV

Guinness Asset Management LTD lifted its holdings in AbbVie Inc. (NYSE:ABBV) by 0.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,210,293 shares of the company’s stock after purchasing an additional 4,268 shares during the period. AbbVie comprises approximately 4.3% of Guinness Asset Management LTD’s portfolio, making the stock its 5th largest holding. Guinness Asset Management LTD’s holdings in AbbVie were worth $270,089,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter worth $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the second quarter worth about $36,000. Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie in the 2nd quarter worth about $39,000. Finally, Access Investment Management LLC bought a new stake in AbbVie in the 2nd quarter valued at about $44,000. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and 2026 outlook raised — AbbVie reported Q4 revenue and adjusted EPS above estimates and issued 2026 adjusted EPS guidance that tops Street views, driven by strong immunology sales. AbbVie forecasts 2026 profit above estimates
• Positive Sentiment: Skyrizi & Rinvoq are the growth engines — Management said Skyrizi and Rinvoq grew strongly (double‑digit/30%+ rates in 2025), offsetting a smaller‑than‑expected Humira decline and driving the company’s top‑line beat. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Analyst/institutional support — Morgan Stanley nudged up its price target and several analysts/institutions are still accumulating shares, which supports upside case and dividend safety arguments cited by bulls. Analyst price target raise
• Positive Sentiment: Favorable real‑world Rinvoq data — New Japan real‑world data for Rinvoq could expand label/market confidence for ankylosing spondylitis and support future sales momentum. Rinvoq real-world data in Japan
• Neutral Sentiment: Market technical/positioning view — Some commentators describe the post‑earnings pullback as a buying opportunity, citing institutional accumulation and dividend support; this is sentiment/flow driven rather than new fundamental news. MarketBeat dip-is-buy analysis
• Neutral Sentiment: IPR&D / milestone accounting affects comparability — 2025 and some Q4 results include one‑time IPR&D/milestone impacts that complicate GAAP vs. adjusted comparisons; management’s 2026 guidance excludes future IPR&D burdens. PR Newswire results & IPR&D note
• Negative Sentiment: Near‑term guidance and Q1 caution — AbbVie set Q1 2026 EPS guidance below some quarterly consensus and issued a slightly softer near‑term revenue tone (market focused on the lower quarterly guide even as full‑year was raised), which contributed to short‑term selling pressure. Earnings call / transcript
• Negative Sentiment: Diversification worries — Analysts flagged weakness in oncology and aesthetics and questioned growth durability beyond immunology, fueling debate about reliance on M&A and milestones to sustain long‑term growth. Seeking Alpha downgrade on diversification
• Negative Sentiment: Rinvoq expansion/valuation questions — Strategic moves such as the Rinvoq vitiligo push raise questions about incremental costs and valuation expectations, which could pressure sentiment if approval/commercial returns are uncertain. Rinvoq vitiligo valuation questions

Wall Street Analyst Weigh In

Several research firms have commented on ABBV. Piper Sandler restated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research report on Tuesday, November 4th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Finally, Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $218.44 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market cap of $386.06 billion, a P/E ratio of 92.56, a PEG ratio of 0.89 and a beta of 0.35. The stock has a fifty day moving average price of $223.81 and a two-hundred day moving average price of $219.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the previous year, the business earned $2.16 EPS. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.